Retrospective cohort study explores HBsAg loss affecting clinical outcomes in chronic hepatitis B, suggesting vital implications.
Introduction: Chronic hepatitis B virus infection (CHB) is a major public health concern and liver-related complications are a leading cause of mortality in this population. The impact of loss of hepatitis B surface antigen (HBsAg), a marker of functional cure for CHB, on clinical outcomes remains unclear in a US population.
No takes yet. Share an insight, caveat, or question.
Drysdale et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: